CureVac collaborates with GSK to Initiate P-I/II study of Avian Influenza (H5N1)
Shots:
- CureVac announced initiation of P-I part of P-I/II study to evaluate influenza A (H5N1) pre-pandemic vaccine (up to 5 dose levels vs PBO) in collaboration with GSK
- P-I/II study assess safety, reactogenicity and immunogenicity of Influenza A (H5N1) pre-pandemic monovalent vaccine in healthy young (18-64yrs.) & old adults (65-85yrs) in US
- The CureVac-GSK collaboration announced in Jul’20 focusses on using CureVac’s mRNA technology to develop infectious disease products
Ref: CureVac | Image: CureVac
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
